Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592995 · ClinicalTrials.gov registry record · Phase 2
Creatine Safety and Tolerability in Premanifest HD: PRECREST
A Phase 2 study of Huntington Disease, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT00592995: Completed Phase 2 study of Huntington Disease, sponsored by Massachusetts General Hospital.
NCT00592995 is a Phase 2 study of Huntington Disease that has completed, run by Massachusetts General Hospital. The registered enrollment target is 64 participants, below the 634-participant average among 35 other Huntington Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00592995, a Phase 2 study of Huntington Disease, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
PRECREST is a two phase protocol for Huntington's disease in which 60 premanifest and at-risk subjects will first be randomized into a double blind placebo controlled dose titration study bringing them to 30 grams daily or their highest tolerated dose. This phase will establish the highest tolerable doses in premanifest HD and permit the detection of toxicity and intolerability with attribution to active compound versus placebo, and enable a dose response assessment of biomarkers. In the second phase, all subjects will enter a year long open-label treatment on 30 grams daily (or their highest dose) of creatine to assess long term exposure to high dose creatine and its long term impact on various biomarkers.
Primary Outcome
Tolerability (proportion of subjects completing study at given dose level)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Creatine monohydrate
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT00592995 record still lists
NCT00592995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 634-participant average among 35 other Huntington Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00592995 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00592995 about?
NCT00592995 is a clinical study titled "Creatine Safety and Tolerability in Premanifest HD: PRECREST". PRECREST is a two phase protocol for Huntington's disease in which 60 premanifest and at-risk subjects will first be randomized into a double blind placebo controlled dose titration study bringing them to 30 grams daily or their highest tolerated dose. This phase will establish the highest tolerable...
What is the current status of trial NCT00592995?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2007-12. Estimated completion is 2012-09.
What conditions does trial NCT00592995 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT00592995?
The interventions under investigation include: Placebo (DRUG), Creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT00592995?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00592995 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00592995's enrollment target sits among peer trials
64 23rd of 35 higher than 13 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia